Oncternal Therapeutics Inc

0.00 (-0.93%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)18.87M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.18 Million
Adjusted EPS-$0.14
See more estimates
10-Day MA$0.32
50-Day MA$0.35
200-Day MA$0.60
See more pivots

Oncternal Therapeutics Inc Stock, NASDAQ:ONCT

12230 El Camino Real, Suite 230, San Diego, California 92130
United States of America
Phone: +1.858.434.1113
Number of Employees: 30


Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Its product pipeline include Zilovertamab, ONCT-216, ONCT-808 and ONCT-534. The company was founded by David F. Hale and James B. Breitmeyer in September 1997 and is headquartered in San Diego, CA.